Endomyocardial (eosinophilic) disease
Methodology & AI Transparency ⓘ
Endomyocardial (eosinophilic) disease Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Endomyocardial (eosinophilic) disease—coded clinically as I42.3 across Heart & Vascular guidelines—combines transthoracic echocardiography [Endomyocardial (eosinophilic) disease I42.3] with structured follow-up of NT-proBNP [Endomyocardial (eosinophilic) disease I42.3] (< 100 pg/mL (I42.3)).
- 2 Real-world patient consensus: Clinical coding for Endomyocardial (eosinophilic) disease uses ICD-10 I42.3 across Heart & Vascular specialty care.
- 3 Typical cash cost range: Clinicians assessing Endomyocardial (eosinophilic) disease focus on structural ventricular wall in Endomyocardial (eosinophilic) disease (I42.3: stress) and targeted history.
- 4 Top reported side effects / signs: Objective lab/clinical target for Endomyocardial (eosinophilic) disease: Left Ventricular Ejection in Endomyocardial (eosinophilic) disease (I42.3: Fraction (LVEF)) (55% – 70% (I42.3)) and NT-proBNP [Endomyocardial (eosinophilic) disease I42.3].
Ask our AI Specialists anything about Endomyocardial (eosinophilic) disease
What Is Endomyocardial (eosinophilic) disease?
Endomyocardial (eosinophilic) disease—coded clinically as I42.3 across Heart & Vascular guidelines—combines transthoracic echocardiography [Endomyocardial (eosinophilic) disease I42.3] with structured follow-up of NT-proBNP [Endomyocardial (eosinophilic) disease I42.3] (< 100 pg/mL (I42.3)).
Pathophysiology, Underlying Causes & Clinical Presentation
Pathophysiologically, Endomyocardial (eosinophilic) disease (ICD-10 I42.3) is driven by structural ventricular wall in Endomyocardial (eosinophilic) disease (I42.3: stress); specialists in Heart & Cardiovascular Disease monitor NT-proBNP [Endomyocardial (eosinophilic) disease I42.3] to gauge tissue recovery.
Common Symptoms & Clinical Signs
- • Presentation of Endomyocardial (eosinophilic) disease (I42.3): exertional chest pressure in Endomyocardial (eosinophilic) disease (I42.3: or retrosternal tightness)
- • Secondary Endomyocardial (eosinophilic) disease clinical sign: shortness of breath in Endomyocardial (eosinophilic) disease (I42.3: when climbing stairs)
- • Symptom flares in Endomyocardial (eosinophilic) disease correlating with Left Ventricular Ejection in Endomyocardial (eosinophilic) disease (I42.3: Fraction (LVEF)) deviation outside 55% – 70% (I42.3)
- • Functional heart & vascular impact requiring transthoracic echocardiography [Endomyocardial (eosinophilic) disease I42.3] evaluation (I42.3)
Endomyocardial (eosinophilic) disease Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | I42.3 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Heart & Cardiovascular Disease | NLM Clinical Tables |
| Diagnostic / Lab Marker: Left Ventricular Ejection in Endomyocardial (eosinophilic) disease (I42.3: Fraction (LVEF)) | 55% – 70% (I42.3) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: NT-proBNP [Endomyocardial (eosinophilic) disease I42.3] | < 100 pg/mL (I42.3) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: High-Sensitivity Troponin I [Endomyocardial (eosinophilic) disease I42.3] | < 14 ng/L (I42.3) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Endomyocardial (eosinophilic) disease
Treatment selection for Endomyocardial (eosinophilic) disease depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Endomyocardial (eosinophilic) disease)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Aspirin dose, urinary thromboxane and prostacyclin metabolites, and clinical: What a 275-Participant Study Found In acute coronary syndrome, higher-dose aspirin modestly reduced urinary thromboxane without lowering the urinary prostacyclin metabolite. Thrombosis research • 2026-08-15 • Phase III Randomized Trial | N = 275 | 87/100 | PMID 42508308 ↗ |
| Rosuvastatin vs. Simvastatin/ezetimibe on arterial wall stiffness: Which Works Better for Coronary artery disease? Compared with simvastatin/ezetimibe (10/10 mg), rosuvastatin (10 mg) appears to more effectively improve arterial wall stiffness that may be mediated by modulation of the ROCK activity. Internal medicine (Tokyo, Japan) • 2013-01-15 • Randomized Controlled Trial | N = 36 | 82/100 | PMID 24334573 ↗ |
Endomyocardial (eosinophilic) disease Patient Community & “People Like Me” Threads
Filter Endomyocardial (eosinophilic) disease community threads and patient logs by age, biological sex, dosage, and treatment duration.